A team of lawyers from McGuireWoods’ Brussels office helped Belgium-based
Pluriomics establish Ncardia — a new privately held biotech group with
operations in Europe and the United States — through a complex cross-border
merger with its German-based competitor Axiogenesis.
Ncardia secured an additional €4.25 million investment from existing
investors Vesalius Biocapital, SFPI/FPIM and Sambrinvest as a direct result
of the merger,
Ncardia produces and commercializes high-quality, fully functional human
induced pluripotent stem cells (hiPSC) and develops and realizes
electrophysiology-, biochemistry- and contraction-based assays for
predictive safety pharmacology, toxicology testing and drug efficacy
The combined business allows Ncardia to build on more than two decades of
knowledge, stem cell product research and development, and
commercialization by Pluriomics and Axiogenesis.
Led by partner
Timothy Speelman, the McGuireWoods team that represented Pluriomics included partners Hubert André-Dumont
and Paul Van den Bulck
and associates Nathalie Locht
Raphael Krowicki. The Brussels M&A team is listed in
The Legal 500 UK 2016 guide
and was named
Best Private M&A Law Firm in Belgium
for 2016 by Acquisition International magazine.